Definitive Healthcare (DH) Posts US$9.3 Million Q4 Loss Testing Profit Turnaround Hopes

Definitive Healthcare (DH) has just closed out FY 2025 with Q4 revenue of US$61.5 million and a basic EPS loss of US$0.09, alongside trailing twelve month revenue of US$241.5 million and a TTM basic EPS loss of US$1.30. This gives investors a clear read on the current earnings profile. Over the past few quarters, revenue has ranged from US$59.2 million to US$62.7 million, while quarterly basic EPS losses have moved between US$0.07 and US$1.12. This sets the backdrop for a business that is still working through loss-making margins, with investor attention on how quickly profitability might tighten up from here.

See our full analysis for Definitive Healthcare.

With the latest numbers on the table, the next step is to see how this earnings picture lines up with the widely followed narratives around Definitive Healthcare's long term growth potential and risk profile.

See what the community is saying about Definitive Healthcare

Losses Still Heavy At US$138.9 Million TTM

• Over the last twelve months, Definitive Healthcare booked a net loss of US$138.9 million on US$241.5 million of revenue, with trailing EPS at a loss of US$1.30.
• Bulls argue that expanding differentiated data, AI analytics, and deeper client integrations can eventually support better margins. However, the current loss level and a five year history where losses increased at about 56.4% per year show how much ground needs to be covered before that optimistic view lines up with the reported numbers.
  • The bullish narrative talks about strong cash generation and margin expansion potential. At the same time, the latest year still shows a triple digit million loss and trailing revenue that has sat in the mid US$240 million range.
  • Supporters focus on customer stickiness and upsell potential, but the trailing figures highlight that any future earnings recovery would be starting from a deeply loss making base.

Bulls who see a future earnings turnaround starting from a US$138.9 million loss may want to understand how that thesis is built out over the next few years, so it is worth reading the detailed optimistic case for the stock in full 🐂 Definitive Healthcare Bull Case

Quarterly Loss Per Share Narrows From Early FY 2025

• Within FY 2025, net loss excluding extra items moved from US$107.2 million in Q1 to US$9.3 million in Q4, with basic EPS shifting from a Q1 loss of US$0.95 to a Q4 loss of US$0.09 across fairly steady quarterly revenue between US$59.2 million and US$61.5 million.
• Bears point to tightening data privacy rules, industry consolidation, and pricing pressure as long term headwinds. This view is framed against the fact that full year TTM revenue of US$241.5 million is close to the US$252.2 million TTM level reported a year earlier while losses have been large across the period.
  • Bears highlight the risk that healthcare clients bring analytics in house, which would matter if subscription revenue stays flat around the current TTM level instead of growing to match the more optimistic revenue assumptions mentioned in their downside scenario.
  • The cautious narrative also flags restricted IT budgets, and the recent pattern of revenue hovering in the low US$60 million range per quarter gives critics support to question how quickly Definitive Healthcare can grow out of its cost base.

For readers weighing whether recent quarterly loss per share moves really change the cautious view that privacy rules and client consolidation could cap growth, it is helpful to see how the more skeptical thesis is laid out in one place 🐻 Definitive Healthcare Bear Case

Cheap P/S At 0.4x Versus DCF Value Of US$3.14

• The stock trades on a P/S of 0.4x versus a peer average of 0.7x and a US Healthcare Services industry average of 2.2x, and also sits below a DCF fair value of US$3.14 while the current share price is US$0.92 and the analyst price target cited in the data is US$2.41.
• Analysts' balanced narrative highlights a mix of improving retention efforts and ongoing revenue pressure. The valuation gap cuts both ways because the low P/S and discount to DCF fair value sit alongside guidance that points to revenue expected to decline around 2.6% per year over the next three years.
  • The same dataset that shows the P/S discount also records that the company was unprofitable over the last twelve months, so the case for re rating relies heavily on forecast profit improvement from a loss of US$138.9 million to positive earnings over time.
  • At the same time, the consensus price target of US$2.41 is well above the current US$0.92 share price, which reflects how analysts balance expectations of better margins against the history of widening losses mentioned in the five year loss growth rate of about 56.4% per year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Definitive Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers and narratives so far? Use this as a prompt to review the full data, rigorously examine both sides of the argument, and carefully weigh the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Definitive Healthcare is still working through heavy losses of US$138.9 million on US$241.5 million of revenue and an extended period of unprofitable operations.

If this mix of ongoing losses and uncertainty around future earnings feels uncomfortable, use the 72 resilient stocks with low risk scores to quickly focus on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com